CME

Host: Christopher B. Granger, MD Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.

Host: Elaine Hylek, MD, MPH Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.

Host: M. Cecilia Bahit, MD Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.

Host: Manesh R. Patel, MD Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.

Host: Manesh R. Patel, MD Host: M. Cecilia Bahit, MD Host: Elaine Hylek, MD, MPH Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.

Host: Joshua E. Reuss, MD Host: Jessica S. Donington, MD, MSCR The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria. Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.

Host: Joshua E. Reuss, MD Host: Jessica S. Donington, MD, MSCR The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria. Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.

Host: Joshua E. Reuss, MD Host: Jessica S. Donington, MD, MSCR The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria. Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.

Host: Michael J. Cuttica, MD, MS The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

Host: Vallerie V. McLaughlin, MD The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

Host: Vallerie V. McLaughlin, MD Host: Ruben Mylvaganam, MD Host: Michael J. Cuttica, MD, MS The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

Host: George Hanna, MD The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

Host: Ruben Mylvaganam, MD The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

Host: Daniel Schimmel, MD The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.

Host: Jonathan Haft, MD The Midwest Regional Pulmonary Hypertension Summit occurred on October 14, 2023, in Chicago, IL. The event highlighted the management of PH with other coexisting comorbidities. Leading experts discussed the appropriate risk stratification, management of PH, updates on ERS/ERC guidelines, and optimal patient care practice.